72 results on '"Bolstad, Nils"'
Search Results
2. Coeliac disease in the Trøndelag Health Study (HUNT), Norway, a population-based cohort of coeliac disease patients
3. Therapeutic Drug Monitoring: A Tool to Optimize Treatment of Inflammatory Joint Diseases
4. Insulin autoimmune syndrome: not just one but two different diseases with therapeutic implications
5. Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases
6. HLA‐DQ2 is associated with anti‐drug antibody formation to infliximab in patients with immune‐mediated inflammatory diseases
7. Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring
8. Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type
9. Transplacental passage of belimumab during pregnancy and follow-up of a child exposed in utero
10. Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
11. The development and validation of a high-capacity serological assay for celiac disease
12. Sa1261: THE DEVELOPMENT AND VALIDATION OF A HIGH CAPACITY SEROLOGICAL ASSAY FOR COELIAC DISEASE
13. 231: PROACTIVE THERAPEUTIC DRUG MONITORING IS SUPERIOR TO STANDARD TREATMENT DURING MAINTENANCE THERAPY WITH INFLIXIMAB; RESULTS FROM A 52-WEEK MULTICENTRE RANDOMISED TRIAL OF 450 PATIENTS
14. 101: GENETIC PREDISPOSITION TO INFLIXIMAB IMMUNOGENICITY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES – SECONDARY ANALYZES FROM A RANDOMIZED TRIAL
15. Sa1248: SCREENING FOR ADULT CELIAC DISEASE IN THE GENERAL POPULATION
16. Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial
17. Drug Levels Associated With Optimal Discrimination Between Remission and Nonremission and Comparison of Antibody Assays During First Year of Stable Infliximab Maintenance Therapy in Inflammatory Bowel Disease
18. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases
19. Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis
20. Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases—Reply
21. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases
22. Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort
23. Colorectal Cancer Screening With Repeated Fecal Immunochemical Test Versus Sigmoidoscopy: Baseline Results From a Randomized Trial
24. Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease
25. Falsely markedly elevated 25-hydroxyvitamin D in patients with monoclonal gammopathies
26. The effect of infliximab in patients with chronic low back pain and Modic changes (the BackToBasic study): study protocol of a randomized, double blind, placebo-controlled, multicenter trial
27. Maternal placental growth factor and soluble fms-like tyrosine kinase-1 reference ranges in post-term pregnancies: A prospective observational study
28. Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
29. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma
30. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease
31. OXR1A, a Coactivator of PRMT5 Regulating Histone Arginine Methylation
32. Exploratory Analysis of CA125-MGL and –STn Glycoforms in the Differential Diagnostics of Pelvic Masses
33. Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
34. Kjell Johannes Nustad
35. Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study
36. Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (The NOR-DRUM study)
37. Determination of lower cut‐off levels of adalimumab associated with biochemical remission in Crohn's disease
38. Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (The NOR-DRUM study)
39. 44 – Infliximab Clearance is Decreased During 2Nd and 3Rd Trimesters of Pregnancy in Inflammatory Bowel Disease
40. A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients
41. Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort
42. Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
43. LYMRIT 37-01: A Phase I/II Study of 177lu-Lilotomab Satetraxetan (Betalutin®) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up
44. Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity
45. Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study
46. Auto-antibodies against the angiotensin II type I receptor in women with uteroplacental acute atherosis and preeclampsia at delivery and several years postpartum
47. Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
48. Switching from originator to biosimilar infliximab – real world data of a prospective 18 months follow-up of a single-centre IBD population
49. 815 - Long-Term Efficacy and Safety of CT-P13 after Switching from Originator Infliximab: Exploratory Subgroup Analyses in IBD in the Nor-Switch Extension Trial
50. Lowered reference limits for hCG improve follow-up of patients with hCG-producing tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.